Novartis Ag (NVS) Payables (2009 - 2026)
Novartis Ag (NVS) posted Payables of $4.3 billion for Q2 2026, down 17.13% sequentially from $5.1 billion in Q4 2025, and down 5.5% YoY from $4.5 billion in Q2 2025.
Novartis Ag (NVS) Payables (2009 - 2026) Analysis & Trends
Novartis Ag has reported Payables for 18 years, with the latest figure at $4.3 billion in Q2 2026.
- Quarterly Payables fell 5.5% year-over-year to $4.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.3 billion (down 5.5% YoY) and the FY2025 annual result came in at $5.1 billion, up 1389.28% from the prior year.
- Payables fell to $4.3 billion in Q2 2026 per NVS's latest filing, from $5.1 billion in the prior quarter.
- Over five years, Payables peaked at $6.0 billion in Q4 2022 and troughed at -$290.0 million in Q3 2024.
- A 5-year average of $2.5 billion and a median of $2.3 billion in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables plunged 2166.67% in 2022, then surged 7967.65% in 2023.
- Over 5 years, Payables stood at $6.0 billion in 2022, then plunged by 93.46% to $393.0 million in 2023, then dropped by 12.21% to $345.0 million in 2024, then soared by 1389.28% to $5.1 billion in 2025, then declined by 17.13% to $4.3 billion in 2026.
- According to Business Quant data, Payables over the past three periods registered $4.3 billion, $5.1 billion, and $4.5 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 20.92 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.30 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 5.96 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.26 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 22.89 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 2.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 674.00 Mn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 7.03 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -25.00 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 8.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.26 Bn |
| Dec 31, 2025 | 5.14 Bn |
| Jun 30, 2025 | 4.51 Bn |
| Dec 31, 2024 | 345.00 Mn |
| Sep 30, 2024 | -290.00 Mn |
| Jun 30, 2024 | 4.15 Bn |
| Dec 31, 2023 | 393.00 Mn |
| Jun 30, 2023 | 5.35 Bn |
| Dec 31, 2022 | 6.01 Bn |
| Sep 30, 2022 | -68.00 Mn |
| Jun 30, 2022 | -68.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 6.45 Bn |
| Sep 30, 2021 | -3.00 Mn |
| Jun 30, 2021 | -3.00 Mn |
| Mar 31, 2021 | -3.00 Mn |
| Dec 31, 2020 | 832.00 Mn |
| Sep 30, 2020 | -144.00 Mn |
| Jun 30, 2020 | -144.00 Mn |
| Mar 31, 2020 | -144.00 Mn |